通过先进的WuXiDARx偶联技术助力新一代ADC和XDC的研发

Background: Antibody drug conjugates (ADCs) and various types of bioconjugates (XDCs) have garnered increasing attention over the past decade. These novel payloads and payload combinations require advanced conjugation technologies to fully achieve their therapeutic potential. Conventionally, interchain cysteine coupling serves as the most clinically validated conjugation technologies. However, such methods have two major flaws: (1) heterogeneity from stochastic coupling (except for DAR8); and (2) instability during circulation due to maleimide retro-Michael addition. Solutions: To address these needs, WuXi XDC has built a platform through internal development and external collaboration. This platform includes two parts: (1) WuXiDARx™ conjugation technology WuXiDARx™ conjugates at interchain cystines which are the most clinical validated site, as 13 out of 18 commercial ADCs are developed through cysteine conjugation. This technology features: • Flexible DAR choices (WuXiDAR1 TM , WuXiDAR2 TM , WuXiDAR4 TM , WuXiDAR6 TM ) • Improved homogeneity: ≥ 85% for DAR1 and DAR2; or ≥ 65% for DAR4 and DAR6 • Enhanced efficacy and safety profiles • Compatibility with IgG1 mAb • Compatibility with novel ADCs (e.g., dual-payload ADCs, bispecific ADCs) and XDCs (e.g., AOCs, APCs) • Simple and robust conjugation process • Validated technology: 7 ADCs in clinical trials, 10 CMC projects, up to > 2 kg batch size (2) Thiol reactive connector technologies Conventional interchain cysteine conjugation uses maleimide connector to react with the thiol groups from the antibody. However, the reverse reaction (retro-Michael addition) may result in premature release of the payload-linkers in circulation. To solve this problem, X-LinC connector is developed to replace the maleimide connector, which has shown good plasma stability and is fully compatible with WuXiDARx TM . A different way to create homogeneous DAR4 ADCs is by using thiol-rebridging connectors. CysLink technology incorporates a stable thiol-rebridging connector into the platform. Unlike traditional connectors, the CysLink version produces ADCs with fewer thiol mismatches and half-antibody ratios, and it works with WuXiDARx TM to offer additional DAR options (e.g., DAR1). Conclusion: The combination of WuXiDARx TM , X-LinC, and CysLink offers an integrated solution to utilize the most clinically validated conjugation sites, which is helping accelerate ADCs/XDCs pipeline development from clients.